Joined October 2020
546 Photos and videos
Juisci turns peer-reviewed science into #HCP engagement your medical & marketing teams can actually prove : reach, engagement, time saved. See it live this week at VivaTech, Sanofi Startup Corner. #VivaTech #Sanofiโ€จ#IA
19
Exercising harder may matter more than exercising more. A recent study published in European Heart Journal, based on data from nearly 500,000 UK Biobank participants, suggests that higher-intensity activity is associated with lower risk of cardiovascular events, atrial fibrillation, type 2 diabetes, inflammatory diseases, metabolic liver disease, respiratory diseases, chronic kidney disease, and dementia, as well as all-cause mortality, regardless of total exercise volume. These findings suggest that, beyond simply doing more exercise, incorporating higher-intensity efforts may offer meaningful health benefits, provided they are carefully tailored to each individual. ๐Ÿ‹ Want to dive deeper? Explore this study and more by downloading the Juisci app #ChronicDiseasePrevention #ExerciseMedicine #PhysicalActivity #CardiovascularHealth #HighIntensityExercise #EvidenceBasedMedicine #EuropeanHeartJournal
1
96
๐Ÿ’ก Recurrent miscarriage: hydroxychloroquine should not be routine In a multicentre, randomised, placebo-controlled phase 3 trial, hydroxychloroquine started before conception and continued until 10 weeksโ€™ gestation did not improve livebirth rates versus placebo.
1
2
59
Livebirth occurred in 58% of women receiving hydroxychloroquine and 61% receiving placebo, with no significant between-group difference.
1
45
For clinicians, this reinforces a key principle in recurrent miscarriage care: avoid adding empiric treatments without demonstrated benefit. Management should remain focused on appropriate evaluation, clear counselling, and evidence-based supportive care. ๐Ÿ‘‰ Stay ahead of the latest research in medicine by downloading our app (link in comment). #ClinicalResearch #MedicalEducation #EvidenceBasedMedicine #RecurrentMiscarriage #PregnancyLoss #Hydroxychloroquine
25
OpenEvidence just left Europe. ~200,000 European physicians lost access overnight. European HCPs deserve better than clinical AI that can't, or won't meet basic compliance standards. #Juisci has been here since 2021. Built under EU jurisdiction. hashtag #AI Act compliant by design. 40,000 European HCPs, every month. We're not replacing OpenEvidence... yet. But ๐˜„๐—ฒ'๐—ฟ๐—ฒ ๐—ผ๐—ป๐—ฒ ๐—ผ๐—ณ ๐˜๐—ต๐—ฒ ๐—ฒ๐—ฎ๐˜€๐—ถ๐—ฒ๐˜€๐˜ ๐˜„๐—ฎ๐˜†๐˜€ ๐˜๐—ผ ๐˜€๐˜๐—ฎ๐˜† ๐—ผ๐—ป ๐˜๐—ผ๐—ฝ ๐—ผ๐—ณ ๐˜€๐—ฐ๐—ถ๐—ฒ๐—ป๐˜๐—ถ๐—ณ๐—ถ๐—ฐ ๐—น๐—ถ๐˜๐—ฒ๐—ฟ๐—ฎ๐˜๐˜‚๐—ฟ๐—ฒ ๐—ถ๐—ป ๐˜†๐—ผ๐˜‚๐—ฟ ๐—ณ๐—ถ๐—ฒ๐—น๐—ฑ. โ†’ Try Juisci ยท app.juisci.com (free for HCPs) hashtag#BuiltInEurope hashtag#BuiltToLast hashtag#ClinicalAI hashtag#Juisci hashtag#Science hashtag#IA
50
5,000 abstracts. 16,000 experts in Munich. One clear reality: science is moving faster than clinicians can keep up with.
1
31
Here's what that looks like in practice : the playlist related to bioMรฉrieux's symposium on "STRIDES in AMR: Diagnostics driving impact", available in #Juisci App !
1
6
๐Ÿ‘‰ If you missed the bioMรฉrieux symposium at ESCMID โ€” or just want to revisit it without digging through abstracts โ€” this playlist brings together the key publications and clinical takeaways. Built for ID specialists and clinical microbiologists ๐Ÿ‘‡ app.juisci.com/room/playlistโ€ฆ #InfectiousDiseases
22
๐Ÿ’ก New insights in gut microbiome and antimicrobial stewardship This large Swedish population-based study of 14,979 adults demonstrates that oral antibiotic exposure is associated with long-lasting reductions in gut microbial diversity and altered species abundance in a general adult population, persisting up to 8 years after use while underscoring that specific classes drive most of these sustained changes and should factor into long-term prescribing decisions. Swipe through to explore the key findings and their implications for antibiotic prescribing and gut health. ๐Ÿ‘‰ Want a deeper dive ? Chat with the paper in our app (link in bio) #ClinicalResearch #MedicalEducation #EvidenceBasedMedicine #Gastroenterology #Microbiome #InfectiousDisease #AntimicrobialStewardship
39
๐Ÿ’ก New insights in treatment-resistant depression. One day of treatment. That's all it took. In this phase 2b randomized trial (JAMA Psychiatry, 2026), a single session of inhaled mebufotenin (GH001) led to remission in 57.5% of patients with treatment-resistant depression by day 8, versus 0% with placebo. NNT = 2. Effect size = -2.0, a magnitude rarely seen in psychiatry.
1
1
63
Tolerability was reassuring, with no severe adverse events. And among patients in remission at day 8, 87% maintained it at 6 months with only infrequent retreatments. For a population that has failed at least two antidepressants, these results are hard to ignore.
1
16
๐Ÿ‘‰ Stay ahead of the latest research in medicine by downloading our app (link in bio). #ClinicalResearch #MedicalEducation #EvidenceBasedMedicine #Depression #Psychiatry
9
Scientific papers are often : Too long. Too dense. Hard to use quickly. Thatโ€™s exactly why we built this ๐Ÿ‘‡
1
41
No wasted time. No guesswork.
1
4